Photosoft compounds demonstrated ≥99% inhibition against Zika virus in cell-based assays following the application of light. Zika virus is found in 86 countries and has been linked to birth defects and other neurological complications. The Zika virus market is to be worth ~US$17 billion in 2022 with no treatments for the disease currently available. Several…
Read more
INV043 Significantly Improved Checkpoint Inhibitor Therapy
Combination therapy of INV043 and immune checkpoint inhibitors ("ICI") shown to be more effective compared to standalone ICI therapy, resulting in ~65% reduction of tumour size in mice. Despite widespread clinical use as a monotherapy, ICI's effectiveness is typically limited to a smaller proportion of the cancer patient population. (more…)
Read more
Photosoft granted patent protection in Australia
Invion’s licensed PhotosoftTM technology receives patent protection until 2033 PhotosoftTM targeted as a therapy for a range of cancers including ovarian, lung, skin and prostate cancer Melbourne, Australia, 10 September 2018: ASX-listed life sciences company Invion Limited (ASX:IVX) announces the grant in Australia of the patent for chlorin e4 sodium, a new generation photodynamic therapy…
Read more
- 1
- 2